GENETICALLY ENGINEERED T CELLS WITH DISRUPTED CASITAS B-LINEAGE LYMPHOMA PROTO-ONCOGENE-B (CBLB) AND USES THEREOF
A population of genetically engineered T cells, comprising a disrupted cbl-b gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth acti...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WALDNER, Hanspeter TERRETT, Jonathan Alexander GUO, Changan |
| description | A population of genetically engineered T cells, comprising a disrupted cbl-b gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; (c) reduced T cell exhaustion, and (d) enhanced cytotoxicity activity, as compared to non-engineered T cell counterparts.
L'invention concerne une population de lymphocytes T génétiquement modifiés, comprenant un gène cbl-b interrompu. Ces lymphocytes T génétiquement modifiés peuvent comprendre d'autres modifications génétiques, par exemple, un gène CD70 interrompu. La population de lymphocytes T génétiquement modifiés présente un ou plusieurs éléments parmi (a) une activité de croissance cellulaire améliorée; (b) une persistance améliorée; (c) un épuisement des lymphocytes T réduit, et (d) une activité de cytotoxicité améliorée, par comparaison avec des contreparties de lymphocytes T non modifiés. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023119201A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023119201A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023119201A33</originalsourceid><addsrcrecordid>eNqNjLsKwjAUQLs4iPoPF1x0CPQxOSbpbRNIk9LcUjqVInESrdT_xwh-gNOBw-Fsk1eNFklLbswIaGttETssgUCiMR4GTQpK7bu-pagl95q4B8FMLHmNYMamVa7h0HaOHHNWuu-SCThJYcQZuC2h9-iBVDy7ap9sbvN9DYcfd8mxQpKKheU5hXWZr-ER3tPg8jQvsuySpxkviv-qD6_wOGk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>GENETICALLY ENGINEERED T CELLS WITH DISRUPTED CASITAS B-LINEAGE LYMPHOMA PROTO-ONCOGENE-B (CBLB) AND USES THEREOF</title><source>esp@cenet</source><creator>WALDNER, Hanspeter ; TERRETT, Jonathan Alexander ; GUO, Changan</creator><creatorcontrib>WALDNER, Hanspeter ; TERRETT, Jonathan Alexander ; GUO, Changan</creatorcontrib><description>A population of genetically engineered T cells, comprising a disrupted cbl-b gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; (c) reduced T cell exhaustion, and (d) enhanced cytotoxicity activity, as compared to non-engineered T cell counterparts.
L'invention concerne une population de lymphocytes T génétiquement modifiés, comprenant un gène cbl-b interrompu. Ces lymphocytes T génétiquement modifiés peuvent comprendre d'autres modifications génétiques, par exemple, un gène CD70 interrompu. La population de lymphocytes T génétiquement modifiés présente un ou plusieurs éléments parmi (a) une activité de croissance cellulaire améliorée; (b) une persistance améliorée; (c) un épuisement des lymphocytes T réduit, et (d) une activité de cytotoxicité améliorée, par comparaison avec des contreparties de lymphocytes T non modifiés.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230803&DB=EPODOC&CC=WO&NR=2023119201A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25555,76308</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230803&DB=EPODOC&CC=WO&NR=2023119201A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WALDNER, Hanspeter</creatorcontrib><creatorcontrib>TERRETT, Jonathan Alexander</creatorcontrib><creatorcontrib>GUO, Changan</creatorcontrib><title>GENETICALLY ENGINEERED T CELLS WITH DISRUPTED CASITAS B-LINEAGE LYMPHOMA PROTO-ONCOGENE-B (CBLB) AND USES THEREOF</title><description>A population of genetically engineered T cells, comprising a disrupted cbl-b gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; (c) reduced T cell exhaustion, and (d) enhanced cytotoxicity activity, as compared to non-engineered T cell counterparts.
L'invention concerne une population de lymphocytes T génétiquement modifiés, comprenant un gène cbl-b interrompu. Ces lymphocytes T génétiquement modifiés peuvent comprendre d'autres modifications génétiques, par exemple, un gène CD70 interrompu. La population de lymphocytes T génétiquement modifiés présente un ou plusieurs éléments parmi (a) une activité de croissance cellulaire améliorée; (b) une persistance améliorée; (c) un épuisement des lymphocytes T réduit, et (d) une activité de cytotoxicité améliorée, par comparaison avec des contreparties de lymphocytes T non modifiés.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLsKwjAUQLs4iPoPF1x0CPQxOSbpbRNIk9LcUjqVInESrdT_xwh-gNOBw-Fsk1eNFklLbswIaGttETssgUCiMR4GTQpK7bu-pagl95q4B8FMLHmNYMamVa7h0HaOHHNWuu-SCThJYcQZuC2h9-iBVDy7ap9sbvN9DYcfd8mxQpKKheU5hXWZr-ER3tPg8jQvsuySpxkviv-qD6_wOGk</recordid><startdate>20230803</startdate><enddate>20230803</enddate><creator>WALDNER, Hanspeter</creator><creator>TERRETT, Jonathan Alexander</creator><creator>GUO, Changan</creator><scope>EVB</scope></search><sort><creationdate>20230803</creationdate><title>GENETICALLY ENGINEERED T CELLS WITH DISRUPTED CASITAS B-LINEAGE LYMPHOMA PROTO-ONCOGENE-B (CBLB) AND USES THEREOF</title><author>WALDNER, Hanspeter ; TERRETT, Jonathan Alexander ; GUO, Changan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023119201A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>WALDNER, Hanspeter</creatorcontrib><creatorcontrib>TERRETT, Jonathan Alexander</creatorcontrib><creatorcontrib>GUO, Changan</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WALDNER, Hanspeter</au><au>TERRETT, Jonathan Alexander</au><au>GUO, Changan</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>GENETICALLY ENGINEERED T CELLS WITH DISRUPTED CASITAS B-LINEAGE LYMPHOMA PROTO-ONCOGENE-B (CBLB) AND USES THEREOF</title><date>2023-08-03</date><risdate>2023</risdate><abstract>A population of genetically engineered T cells, comprising a disrupted cbl-b gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; (c) reduced T cell exhaustion, and (d) enhanced cytotoxicity activity, as compared to non-engineered T cell counterparts.
L'invention concerne une population de lymphocytes T génétiquement modifiés, comprenant un gène cbl-b interrompu. Ces lymphocytes T génétiquement modifiés peuvent comprendre d'autres modifications génétiques, par exemple, un gène CD70 interrompu. La population de lymphocytes T génétiquement modifiés présente un ou plusieurs éléments parmi (a) une activité de croissance cellulaire améliorée; (b) une persistance améliorée; (c) un épuisement des lymphocytes T réduit, et (d) une activité de cytotoxicité améliorée, par comparaison avec des contreparties de lymphocytes T non modifiés.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023119201A3 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | GENETICALLY ENGINEERED T CELLS WITH DISRUPTED CASITAS B-LINEAGE LYMPHOMA PROTO-ONCOGENE-B (CBLB) AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T04%3A31%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WALDNER,%20Hanspeter&rft.date=2023-08-03&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023119201A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |